# Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

> **NCT06300424** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Gene Mutation

## Interventions

- **DRUG:** almonertinib
- **DRUG:** Carboplatin
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT06300424
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-01-26
- **Final completion:** 2026-04-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06300424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06300424, "Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06300424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*